系列细针穿刺可直采B细胞淋巴瘤免疫治疗患者的恶性及浸润免疫细胞
样本量和质量足以进行流式细胞术和/或单细胞mRNA测序,平均获得12×10^6个细胞,平均细胞活力86%。FNA样本准确反映肿瘤及其微环境,并揭示特定免疫治疗方案的影响。
要点
- 系列FNA可在免疫治疗临床试验中安全、可耐受地反复采集肿瘤细胞。
- FNA样本适用于流式细胞术和单细胞mRNA测序等下游分析。
- FNA直接采样能准确代表肿瘤及其微环境,可用于动态监测治疗效应。
核心结论
- 系列FNA采样在免疫治疗临床试验中成功采集足量优质细胞材料,可扩展用于研究免疫或靶向治疗的动态效应。
研究设计与样本
- 描述性研究,基于4项低级别淋巴瘤原位疫苗接种免疫治疗临床试验,共纳入44例患者。
主要发现
- FNA样本平均获得12×10^6个细胞,平均细胞活力86%。
- 肿瘤淋巴结FNA样本的细胞群体比例和表型与匹配外周血样本显著不同。
- FNA直接采样与手术切除后离体FNA及解离结果比较,证实FNA准确代表肿瘤及微环境。
- 比较免疫治疗靶淋巴结与非治疗肿瘤部位淋巴结的FNA样本,可揭示特定免疫治疗方案的影响。
临床怎么用
- 系列FNA可作为免疫治疗临床试验中动态采集肿瘤和微环境细胞材料的可行方法。
- 采集的FNA材料适用于流式细胞术和单细胞mRNA测序等分析。
局限性
- 原文未明确报告研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fine-needle aspiration (FNA) is used to diagnose malignancies, recurrences, and metastases. The procedure is quick and well tolerated and can be facilitated by ultrasound guidance. METHODS: This article describes the authors' experience in using serial FNA to harvest cellular material during 4 clinical trials of immunotherapy by in situ vaccination in patients with low-grade lymphoma. RESULTS: Two hundred ninety-six FNA samples were collected from 44 patients over a span of approximately 6 weeks for each patient. Samples were sufficient in quantity and quality to be analyzed by flow cytometry and/or single-cell messenger RNA sequencing. FNA samples yielded an average of 12 × 106 cells with a mean cellular viability of 86%. Material collected from the tumor lymph nodes differed significantly in the proportions and phenotypes of cellular populations in comparison with matched peripheral blood samples. A comparison of flow cytometry results obtained by FNA directly from the patient and by FNA performed ex vivo and a dissociation of the same lymph node after surgical excision confirmed that FNA sampling of the patient accurately represented the tumor and the microenvironment. An analysis of the FNA samples from immunotherapy-treated target lymph nodes versus nodes from nontreated tumor sites provided insight into the impact of specific immunotherapy regimens. CONCLUSIONS: This is the largest study describing the use of serial FNA sampling to harvest cellular material during immunotherapy clinical trials. The success of this technique opens the door for FNA sampling to expand significantly future investigations of the dynamic effects of investigational agents, be they immunotherapies or targeted therapies.
引用
- Mooney KL, Czerwinski DK, Shree T, et al. Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy. Cancer Cytopathol. 2021. PMID: 34780125. doi:10.1002/cncy.22531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。